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tia, rather than the atherosclerotic intima, suggesting that
chronic inflammation plays a pivotal role in the destruc-
tion of structural matrix proteins.2,3 Although the factors
responsible for monocyte recruitment into the outer aor-
tic wall are not completely known, they likely include local
production of chemotactic cytokines, adhesion molecules,
and products of matrix degradation.4 Indeed, a number of
chemotactic molecules have been demonstrated in human
AAAs, such as the chemokines monocyte chemotactic pro-
tein-1 (MCP-1) and interleukin-8 (IL-8).5,6 It is also
commonly held that products of elastin degradation might
further act to localize the inflammatory response to the
outer aortic wall in AAAs; thus the “elastin degradation
peptide (EDP) hypothesis” has been proposed as a poten-
tial mechanism underlying the distinct pattern of inflam-
mation observed in aneurysm disease.7,8
Indirect evidence for the EDP hypothesis arises from
the finding that elastic fibers can be used to generate sol-
uble products with chemotactic activity for fibroblasts,
neutrophils, and mononuclear phagocytes.9-11 This has
been demonstrated with intact tropoelastin, soluble forms
of elastin (ie, k-elastin), fragments of elastin produced by
in vitro enzymatic digestion (ie, EDPs), and a specific pep-
tide sequence found in human and bovine tropoelastin,
Chronic inflammation is a characteristic feature of
occlusive atherosclerosis and abdominal aortic aneurysms
(AAAs), but the intensity and extent of the inflammatory
responses are much greater in AAAs than in atherosclero-
sis alone.1 The distribution of inflammatory cells in AAAs
is also concentrated within the elastic media and adventi-
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Background: Chronic inflammation is a characteristic feature of abdominal aortic aneurysms (AAAs), but the molecu-
lar signals responsible for recruiting monocytes into the outer aortic wall are unresolved. The purpose of this study was
to examine whether AAA tissues elaborate chemotactic activity for mononuclear phagocytes and to determine whether
this activity is attributable to interactions between elastin degradation peptides (EDPs) and their cell surface receptor,
the 67-kD elastin binding protein (EBP).
Material and Methods: Soluble proteins were extracted from human AAA tissues, and chemotactic activity for differen-
tiated U937 mononuclear phagocytes was measured by use of a modified Boyden chamber. Chemotactic activity
induced by N-formyl-Met-Leu-Phe was used as a positive control and checkerboard analysis was used to distinguish
chemotaxis from chemokinesis. Inhibition of chemotaxis was tested by peptide competition, blocking antibodies and
galactosugar-mediated dissociation of the 67-kD EBP.
Results: AAA extracts stimulated a concentration-dependent increase in monocyte migration that reached up to 24% of
the maximal effect induced by N-formyl-Met-Leu-Phe. Checkerboard analysis demonstrated that AAA extracts stimu-
lated chemotaxis without a chemokinetic effect. AAA-derived chemotactic activity was eliminated by competition with
Val-Gly-Val-Arg-Pro-Gly (VGVAPG), a repetitive peptide found in human elastin that binds to cellular elastin recep-
tors, and decreased nearly 40% in the presence of BA-4, an antielastin monoclonal antibody that can block EDP-medi-
ated chemotactic activity. Monocyte chemotaxis in response to both VGVAPG and AAA extracts was abolished in the
presence of lactose, a galactosugar that specifically dissociates the 67-kD EBP, but it was unaffected by either glucose,
fructose, or mannose.
Conclusions: These findings indicate that soluble EDPs released within human AAA tissue can subsequently attract
mononuclear phagocytes through ligand-receptor interactions with the 67-kD EBP, thereby providing a plausible mo-
lecular mechanism to explain the inflammatory response that accompanies aneurysmal degeneration. Better under-
standing of factors regulating inflammatory cell recruitment may lead to novel forms of therapy for early stages of
aneurysmal degeneration. (J Vasc Surg 2002;35:254-61.)
Val-Gly-Val-Arg-Pro-Gly (VGVAPG).9-13 Elastin-related
peptides have also been reported to mediate additional
biologic activities, including transmembrane calcium flux,
vasodilation, and matrix metalloproteinase expression.
14-17 These observations have long suggested the existence
of elastin-specific cell surface receptors, and a peripheral
membrane protein that might fill this function was first
identified by Wrenn et al,18 Hinek et al,19 and Mecham et
al.20,21 Indeed, the biologic activities of EDPs are now
believed to be mediated in large part through ligand-
receptor interactions with this cell surface receptor, known
as the 67-kDa elastin-binding protein (EBP).
Hinek22,23 has characterized the structural, biochemi-
cal, and molecular features of the 67-kD EBP, as well as its
functional importance in various tissues. The 67-kD EBP
has been demonstrated to be an enzymatically inactive
splice variant of β-galactosidase,24,25 and in elastin-
producing cells it acts as a chaperone to facilitate intracel-
lular transport of tropoelastin and the extracellular assem-
bly of elastic fibers.26,27 The 67-kD EBP also exists as a
membrane-bound complex in association with two other
subunits, a 61-kD neuraminidase and a 55-kD “protective
protein.”23 In addition to its recognition of elastin-related
peptides, the 67-kD EBP binds several nonidentical
hydrophobic domains on laminin and type IV collagen,
provided they form a similar secondary conformation.21,28
The 67-kD EBP also exhibits galactolectin properties,
with a high affinity for lactose and N-acetylgalactosamine-
rich glycosaminoglycans, such as chondroitin sulfate.19
This interaction is functionally important, in that galacto-
sugar ligands specifically induce conformational changes in
the 67-kD EBP and prompt dissociation of the receptor
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from the cell surface.29 Recently, altered function of the
67-kD EBP has been identified in a number of pathologic
conditions.30-33
In spite of the attractiveness of the “EDP hypothesis”
in helping to explain the pathophysiology of aneurysm dis-
ease, there has been no experimental evidence to date
demonstrating that human AAA tissues release monocyte
chemotactic activity directly attributable to elastin pep-
tides, or that monocyte chemotaxis stimulated by AAA tis-
sue is dependent on interactions with cellular elastin
receptors. The purpose of this study was to examine
whether AAA tissues elaborate chemotactic activity for
human mononuclear phagocytes and to determine
whether this activity is attributable to interactions between
EDPs and the 67-kD EBP.
Fig 1. Monocyte migration in response to AAA extracts. Human
U937 monocytes were added to upper wells of microchemotaxis
chamber, and various dilutions of human AAA extract were added
to lower wells. Cell migration was measured after 3 hours and
expressed as number of migrated cells per HPF, as described in
text. Cells stimulated with 0.1 mmol/L f-MLF were used as pos-
itive control (146 ± 33 cells/HPF). Data represent mean ± SEM
for triplicate wells during same experiment (Asterisk indicates P <
.05 versus medium alone). Similar results were observed with
AAA extracts obtained from three different patients.
Fig 2. Effect of VGVAPG on U937 monocyte migration stimu-
lated by AAA extracts. A, Human U937 monocytes were added
to upper wells of microchemotaxis chamber, and various concen-
trations of f-MLF or VGVAPG were added to lower wells.
Chemotaxis was expressed as number of migrated cells per HPF.
All data represent mean ± SEM for triplicate wells during same
experiment. B, U937 monocytes were added to upper wells of
microchemotaxis chamber in presence of various concentrations
of VGVAPG, and chemotaxis was stimulated by human AAA
extracts (1:25) added to lower wells. Chemotaxis was expressed as
number of migrated cells per HPF. Data represent mean ± SEM
of results from three different AAA extracts tested during the




Preparation of AAA tissue extracts. Fresh full-
thickness specimens of aneurysm wall were obtained from
patients undergoing elective surgical repair for infrarenal
AAAs, according to a protocol approved by the the
Washington University School of Medicine Human
Research Subjects Committee. All aneurysmal wall speci-
mens were obtained from the point of maximal dilation
after the removal of mural thrombus and atherosclerotic
debris. Tissue specimens were immersed in liquid nitrogen
and stored at –70° C until use. Frozen tissue specimens
were weighed and washed with ice-cold phosphate-
buffered saline solution, and soluble proteins were
extracted by incubation in phosphate-buffered saline solu-
tion supplemented with 2 mol/L NaCl for 3 hours at 4°
C with gentle shaking (20 mL/g tissue). The tissue was
removed at the end of the incubation, and the extract was
spun in a centrifuge to remove any particulate debris
(10,000 rpm for 30 minutes). To restore the salt concen-
tration to physiological levels without eliminating low
molecular weight proteins, extract samples were diluted at
least 1:10 in chemotaxis medium consisting of Dulbecco’s
modified essential medium supplemented with 1% lactal-
bumin hydrolysate (Sigma Chemical Co, St Louis, Mo).
U937 mononuclear phagocytes. Human U937
monocytic cells were purchased from the American Type
Culture Collection (ATCC catalog number CRL-1593.2,
Manassas, Va). Cells were maintained in suspension cul-
ture in T-75 flasks containing RPMI 1640 medium sup-
plemented with 10% fetal calf serum and antibiotics, and
cultures were split every 3 to 5 days. Three days before use
in chemotaxis assays, U937 cells were stimulated to differ-
entiate along the macrophage lineage by exposure to 1
mmol/L dibutyryl cyclic adenosine monophosphate
(dbcAMP; Sigma Chemical Co), as described.34-36 Cells
were washed three times to remove culture medium and
then resuspended in chemotaxis medium (Dulbecco’s
modified essential medium supplemented with 1% lactal-
bumin hydrolysate) for plating into assay chambers at a
final concentration of 2.5 × 106 cells/mL.
Monocyte migration assays. Chemotaxis assays were
performed in 48-well microchemotaxis chambers (Neuro
Probe, Cabin John, Md), as described elsewhere.37 The
bottom wells of the chamber were filled with 25 mL of the
chemotactic stimulus (or medium alone) in triplicate. An
uncoated 10-mm–thick polyvinylpyrrolidone-free polycar-
bonate filter with a pore size of 5 mm was placed over the
samples (Neuro Probe). The silicon gasket and the upper
pieces of the chamber were applied, and 50 mL of the
U937 monocyte cell suspension were placed into the
upper wells. Chambers were incubated in a humidified 5%
CO2 atmosphere for 3 hours at 37° C, and nonmigrated
cells were gently wiped away from the upper surface of the
filter. The filter was immersed for 30 seconds in a
methanol-based fixative and stained with a modified
Wright-Giemsa technique (Protocol Hema 3 stain set;
Biochemical Sciences, Inc, Swedesboro, NJ) and then
mounted on a glass slide. Cells that had completely
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migrated through the filter were counted under light
microscopy, with 3 random high-power fields (HPF; orig-
inal magnification × 400) counted per well. 
Experimental manipulations. Maximal chemotactic
activity was measured with 0.1 mmol/L N-formyl-
methionyl-leucyl-phenylalanine (f-MLF; Sigma Chemical
Co), and checkerboard analysis was used to distinguish
chemotaxis from chemokinesis.38,39 Inhibition of chemo-
taxis was tested by competition with VGVAPG, a repeti-
tive peptide sequence found in human and bovine elastin
(Sigma Chemical Co), and BA-4, an antielastin-blocking
antibody.40,41 Controls for BA-4 included mouse
immunoglobulin G (IgG; PharMingen, San Diego, Calif).
Exposure of cells to lactose was used to specifically disso-
ciate the 67-kD EBP. Controls for lactose included glu-
cose, fructose, and mannose, none of which affect the
67-kD EBP. In each case, U937 cells were exposed to the
relevant concentrations of VGVAPG (10–9 to 10–5
mol/L), antibodies (1:1000), or sugars (1 mmol/L) for
30 minutes before the chemotaxis assays were started.
Statistical analysis. Unless otherwise indicated, all
data shown represent the mean ± SEM for triplicate deter-
minations under the same experimental conditions. All
experiments were performed at least three times, with
AAA extracts obtained from different patients. Pairwise
comparisons were made by use of the Student t test, and
multiple comparisons were made by analysis of variance
with the Student-Newman-Keuls test.
RESULTS
Stimulation of monocyte chemotaxis by AAA
extracts. As shown in Fig 1, AAA extracts stimulated a sig-
nificant increase in U937 monocyte migration compared
with medium alone. The activity of AAA extracts consis-
tently occurred in a concentration-dependent manner; in
the example shown this reached a mean of 37 ± 6
cells/HPF (at 1:10 dilution) compared with 15 ± 5
cells/HPF for medium controls, representing an increase
in cell migration of 145%. The maximal monocyte migra-
tion stimulated by AAA extracts was approximately 25% of
that stimulated by 0.1 mmol/L f-MLF, but the need to
dilute AAA extract samples precluded an accurate compar-
ison of specific activities between the two stimuli. As shown
in the Table, checkerboard analysis demonstrated that the
monocyte migration induced by AAA extracts was specifi-
cally due to directional movement (chemotaxis) rather than
a simple increase in random motion (chemokinesis).
Competition with VGVAPG. U937 monocyte
chemotaxis was also stimulated by VGVAPG, a repetitive
amino acid sequence found in human elastin (Fig 2,A).
VGVAPG induced chemotaxis in a concentration-depen-
dent manner with maximal activity at 0.1 mmol/L, and it
was considerably more potent than the same concentra-
tion of f-MLF. To examine whether EDPs might be
responsible for the chemotactic activity stimulated by AAA
extracts, U937 monocytes in the upper wells of the assay
chamber were exposed to varying concentrations of
VGVAPG for 30 minutes before stimulation by AAA
extracts in the lower wells. As shown in Fig 2,B, exposure
of cells to VGVAPG eliminated monocyte chemotaxis
induced by AAA extracts, a result consistent with compe-
tition by the peptide for cellular elastin binding sites. In
contrast, preincubation of U937 cells with VGVAPG did
not alter the chemotactic response to f-MLF (data not
shown).
Effect of antielastin antibodies. An antibody-block-
ing approach was used to further evaluate whether the
chemotactic activity of AAA extracts might be due to the
presence of biologically active EDPs. In preliminary exper-
iments neither BA-4 or IgG alone had any influence on
basal or f-MLF-induced U937 monocyte migration at a
dilution of 1:1000 (data not shown), but BA-4 success-
fully inhibited monocyte chemotaxis induced by VGVAPG
(Fig 3,A). Similarly, monocyte chemotaxis stimulated by
AAA extracts was reduced up to 38% in the presence of
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Fig 3. Effect of BA-4 antibody on U937 monocyte migration
stimulated by VGVAPG and human AAA extracts. A, U937
monocyte chemotaxis was stimulated with 0.1 mmol/L
VGVAPG alone, or same concentration of VGVAPG preincu-
bated for 30 minutes with either mouse IgG or BA-4 antibodies
(1:1000). Chemotaxis was expressed as number of migrated cells
per HPF. Data represent mean ± SEM for triplicate wells during
same experiment. B, U937 monocyte chemotaxis was stimulated
with AAA extracts alone (1:25), or same AAA extracts preincu-
bated for 30 minutes with either mouse IgG or BA-4 antibodies
(1:1000). Chemotaxis was expressed as number of migrated cells
per HPF. Data represent mean ± SEM of results from three dif-
ferent AAA extracts tested during same experiment. Asterisks indi-
cate P < .05 versus medium alone.
Fig 4. Effect of elastin receptor dissociation on U937 monocyte
migration stimulated by VGVAPG or human AAA extracts. A,
U937 monocytes were exposed to 1 mmol/L lactose for 30 min-
utes, and chemotaxis was stimulated with varying concentrations
of VGVAPG. Chemotaxis was expressed as number of migrated
cells per HPF. Data represent mean ± SEM for triplicate wells
during same experiment. B, U937 monocytes were exposed to 1
mmol/L lactose, glucose, fructose, or mannose, and chemotaxis
was stimulated with 10 mmol/L VGVAPG. Chemotaxis was
expressed as number of migrated cells per HPF. Data represent
mean ± SEM for triplicate wells during same experiment. C,
U937 monocytes were exposed to 1 mmol/L lactose, glucose,
fructose, or mannose, and chemotaxis was stimulated with AAA
extract (1:25). Chemotaxis was expressed as number of migrated
cells per HPF. Data represent mean ± SEM for triplicate wells
during same experiment. Similar results were observed with AAA
extracts obtained from three different patients. Asterisks indicate






BA-4, but it was unaffected by an equivalent concentra-
tion of IgG alone (Fig 3,B). These findings provided fur-
ther evidence that at least one third of the monocyte
chemotactic activity in AAA extracts is attributable to the
presence of EDPs.
Dissociation of the 67-kD EBP. To determine
whether the chemotactic activity of AAA extracts might
involve ligand-receptor interactions with the 67-kD EBP
on mononuclear phagocytes, we took advantage of the
unique property of this receptor to dissociate in the pres-
ence of galactosugar ligands (ie, lactose). As shown in Fig
4,A, preexposure of U937 monocytes to 1 mmol/L lac-
tose essentially eliminated cell migration in response to
VGVAPG, even at relatively high concentrations of the
peptide (10 mmol/L). In contrast to the effects of lactose,
VGVAPG-mediated chemotaxis was unaffected by sugars
that do not affect the 67-kD EBP (ie, glucose, fructose,
and mannose) (Fig 4,B). Monocyte chemotaxis in response
to AAA extracts was also abolished in the presence of lac-
tose, but it was similarly unaffected by glucose, fructose,
and mannose (Fig 4,C). In contrast to these results, expo-
sure of cells to lactose had no influence on monocyte
chemotaxis stimulated by f-MLF (data not shown). These
results indicate that monocyte chemotaxis induced by AAA
extracts is largely dependent on the presence of intact cell
surface receptors for elastin-related ligands.
DISCUSSION
The results of this study demonstrate that human AAA
tissues elaborate chemotactic activity for mononuclear
phagocytes. Similar studies have previously shown that
human AAA tissues contain different proteins known to
be chemotactic for mononuclear phagocytes, such as
MCP-1 and IL-8, and that antibodies against these
chemokines can reduce the chemotactic activity released
by explant cultures of human AAA tissue.5,6 Because these
chemokines are generally expressed by inflammatory cells
rather than cell types normally populating the aortic wall,
it is not clear to what extent they might contribute to
monocyte recruitment into the outer aortic wall during
the earliest stages of aneurysmal degeneration. Indeed,
both MCP-1 and IL-8 are expressed in atherosclerotic
plaques, indicating that their presence in AAAs may sim-
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ply be related to the intimal atherosclerosis that accompa-
nies aneurysm disease.42-46 In contrast to the relatively
localized inflammatory response that occurs in atheroscle-
rosis, the distribution of inflammatory cells in AAAs is
largely centered within the degenerative media and adven-
titia, and both MCP-1 and IL-8 have been localized to
macrophages within the outer aortic wall of aneurysm tis-
sue by immunohistochemistry.5 The factors that might
specifically cause recruitment of inflammatory cells into
the elastic media during the early stages of aneurysm dis-
ease are therefore unresolved but potentially important in
understanding the initating mechanisms of aneurysmal
degeneration. 
Because elastin degradation is considered an early
event in aneurysmal degeneration and because elastin is
known to generate biologically-active peptide fragments,
it has long been suspected that EDPs might mediate
inflammatory cell migration into aneurysm tissues. To
specifically test the “EDP hypothesis”, we sought to char-
acterize the chemotactic activity derived from AAA tissue
using several different strategies. First, we used a relatively
gentle tissue extraction technique to isolate soluble pep-
tides by short-term incubation in 2 mol/L NaCl. This
approach was selected to avoid the extraction of insoluble
matrix components and to prevent the release of intracel-
lular proteins that might occur with extensive tissue
homogenization. Although an alternative approach to
these studies might have been to use the conditioned
medium from explants of AAA tissue, we also wanted to
minimize the release of biologically active products that
might arise through tissue necrosis during short-term
explant culture. A second strategy used in these experi-
ments was to avoid desalting the AAA tissue extracts by
traditional dialysis or centrifugal techniques to retain low
molecular weight peptides that might have been released
by elastin degradation in vivo, such as VGVAPG (molecu-
lar weight ~498 d). Finally, we chose to use differentiated
human U937 mononuclear cells for use in the in vitro
chemotaxis assays. Although U937 cells represent a trans-
formed monoblastoid cell line, their in vitro behavior par-
allels that of differentiating human mononuclear
phagocytes, and their response to chemotactic stimuli is
well characterized.47,48 U937 cells were also subjected to
Checkerboard analysis of U937 monocyte migration stimulated by AAA extracts
Upper wells
Lower wells Medium 1:100 1:25 1:10
Medium 13 ± 3 13 ± 1 12 ± 1 14 ± 5
1:100 18 ± 3 18 ± 4 16 ± 3 15 ± 5
1:25 35 ± 5 33 ± 4 14 ± 2 17 ± 1
1:10 37 ± 3 39 ± 2 39 ± 2 9 ± 2
Values are mean ± SE in cells per HPF. Lower wells contained dilutions of AAA extract. Upper wells contained dilutions of AAA extract with U937
mononuclear cells.
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differentiation with cyclic AMP before use in chemotaxis
assays to model the behavior of activated mononuclear
phagocytes that might be attracted into aneurysm tissues
in vivo.34-36
Our experiments were designed to take advantage of
several known properties of EDPs and their interactions
with the 67-kD EBP, such as competition by VGVAPG,
inhibition of EDPs by BA-4 blocking antibodies, and dis-
sociation of the 67-kD EBP complex in the presence of
lactose. VGVAPG is one of several repetitive amino acid
sequences found in human elastin; because this peptide is
known to stimulate monocyte chemotactic activity
through interactions with the 67-kD EBP, the diminished
chemotactic response to AAA extracts in the presence of
VGVAPG is consistent with competition for cellular
elastin receptors. Because the inhibition of chemotaxis did
not appear to be dose-dependent at the concentrations of
VGVAPG tested, it is also possible that low threshold con-
centrations of VGVAPG induced rapid internalization of
the cell surface elastin receptor to make it unavailable for
subsequent interaction with AAA-derived peptides. An
alternative explanation is that the U937 cells preexposed
to VGVAPG in the upper assay chamber were already
maximally stimulated and therefore could not respond in
a directional manner to AAA extract placed in the lower
assay chamber. For these reasons we found it necessary to
adopt additional experimental strategies. The BA-4 anti-
bodies used in this study were originally raised against
VGVAPG, but in previous studies they have been shown
to block biologic responses to a variety of elastin-related
peptides. The observation that incubation of AAA extracts
with BA-4 effectively inhibited chemotaxis thereby sup-
ports the notion that elastin-related peptides are responsi-
ble for much of the activity present in AAA extract
preparations. Although the inhibitory effect of BA-4 was
often incomplete, this most likely reflects variations in
experimental conditions where an inadequate amount of
blocking antibody was present relative to the concentra-
tion of chemotactic EDPs. As discussed earlier, the 67-kD
EBP exhibits several unique features as a cellular elastin
receptor, particularly its selective disruption in the pres-
ence of galactosugar ligands. The selective inhibition of
AAA extract-induced chemotaxis in the presence of lactose
(but not glucose, fructose, or mannose) may therefore be
taken as strong evidence that much of the chemotactic
activity present is mediated by the 67-kD EBP. Because
the 67-kD EBP can recognize peptides related to laminin
and type IV collagen in addition to elastin-related pep-
tides, it remains possible that a portion of the chemotactic
activity present in AAA tissue is related to other biologi-
cally-active products of matrix degradation beyond that
attributable to EDPs alone. 
One limitation of this and similar studies is related to
the use of tissue from established AAAs large enough to
require surgical repair. It is quite possible that the chemo-
tactic activity isolated from these advanced AAA tissues
may not represent the mediators that act during earlier
stages of disease, when the pivotal signals inducing inflam-
matory cell recruitment into the elastic media might be
most active. These experiments nonetheless provide the
first direct evidence indicating the plausibility of the “EDP
hypothesis” with human AAA tissues; indeed, alongside
the recognition that a pronounced degree of elastin deple-
tion is already present in established AAA tissues, it
appears likely that local tissue concentrations of EDPs
might be even higher in earlier stages of the disease than
in the advanced lesions examined here. Further studies
with experimental animal models of aneurysm disease will
be particularly useful in testing the EDP hypothesis in
more detail.
In summary, the findings reported here provide evi-
dence that human AAA tissues contain soluble peptides
capable of specifically directing the migration of mononu-
clear phagocytes and that much of this chemotactic activ-
ity is attributable to peptides released during the process
of elastin degradation. In addition, we have shown for the
first time that ligand-receptor interactions with the 67-
kDa EBP are likely to play a significant role in mediating
inflammatory cell recruitment within AAA tissue.
Although this signaling pathway provides a plausible
mechanism to explain the intensity and localization of
chronic inflammation as it occurs in aneurysmal degener-
ation, better definition of the factors promoting inflam-
mation within AAA tissues is needed. These efforts may
Fig 5. Schematic diagram depicts ligand-receptor interactions
between EDPs, galactosugars, and 67-kD EBP. A, Membrane
receptor complex consists of 67-kD EBP and two associated pro-
teins, which can induce cell signaling on binding to matrix ligands
(EDPs and fragments of laminin or type IV collagen). B,
Receptor complex rapidly dissociates in presence of galactosugar
ligands (ie, lactose or chondroitin sulfate) and is released from cell
surface unable to bind matrix ligands.
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eventually lead to novel forms of therapy for early stages of
aneurysmal degeneration.
We thank Dr. Robert P. Mecham (Department of Cell
Biology and Physiology, Washington University) for pro-
viding the antielastin blocking antibody (BA-4) used in
these experiments.
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CORRECTION
In: “MMP9 production by human monocyte-derived macrophages is decreased on polymerized type I
collagen” (Lepidi S, Kenagy RD, Raines EW, Chiu ES, Chait A, Ross R, Clowes AW. J Vasc Surg
2001;34:1111-8).
As the result of an oversight in printing, the version of this article that appears in the December 2001
print issue is an early draft that does not include the authors’ corrections and contains several errors. The 
publisher and editors apologize. The significant corrections are detailed below.
Please note that the complete, correct version of this article was posted online in the “Upcoming Articles”
section of the Journal’s Web site from October 26, 2001, until the December print issue was published on
December 17, 2001. 
The complete, correct version of this article is now posted in the “December 2001” section of the
Journal’s Web site, www.mosby.com/jvs, and is available free of charge to subscribers. 
On page 1113, 11th line from the bottom, “BSA” was incorrectly spelled out as “benzenesulfonic acid,” and
the amount of ethylenediamine tetraacetic acid (EDTA) is incorrectly given as 50 mmol/L. The sentence should
read, “Conditioned medium was diluted 1-to-1 with PBS containing 0.8% Triton, 1% bovine serum albumin, 5
mmol/L ethylenediamine tetraacetic acid, 5 µg/mL aprotinin...”
Also on page 1113, second line from the bottom, the amount of ethylenediamine tetraacetic acid is incorrectly
given as 50 mmol/L. The sentence should read, “...washed twice with PBS containing 0.4% Triton, 5 mmol/L
ethylenediamine tetraacetic acid, and 1% bovine serum albumin.”
On page 1114, the first sentence on the page should be disregarded.
Also on page 1114, in the second-to-last line of the section titled “DNA assay,” the unit of measure is incor-
rectly given as nmol/L. It should read, “... emission wavelengths of 350 to 360 nm and 520 nm, respectively.”
On page 1116, the column heads for the Table are incorrectly placed. The heading over the first column
should be “Collagen”; over the second column, “TNFα”; over the third column, “Experiment 1”; and over the
fourth column, “Experiment 2.”
The complete, correct version of this article is now posted in the “December 2001” section of the
Journal’s Web site, www.mosby.com/jvs, and is available free of charge to subscribers. 
